Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVMIBY)

Drug Name
AGG-523 Drug Info
Synonyms PF-5212371, WAY-266523
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Phase 1 [1]
Cross-matching ID
PubChem CID
16048422
CAS Number
CAS 920289-29-8
TTD Drug ID
DMVMIBY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aggrecanase (ADAMTS5) TTXSU2Y ATS5_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Aggrecanase (ADAMTS5) DTT ADAMTS5 5.527 6.073 5.885 6.287
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Osteoarthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Aggrecanase (ADAMTS5) DTT ADAMTS5 6.40E-01 0.24 0.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00454298) Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement. U.S. National Institutes of Health.
2 Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23.